{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:43:20Z","timestamp":1777337000486,"version":"3.51.4"},"reference-count":10,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Ophthalmol"],"abstract":"<jats:p>This report presents details on a 45-year-old male Japanese patient with chronic and refractory anterior uveitis associated with psoriasis vulgaris who was administered certolizumab pegol (CZP), which is an anti-tumor necrosis factor alpha (TNF-\u03b1) monoclonal antibody. Although CZP has only been formally approved for rheumatoid arthritis treatment in Japan, a clinical trial allowed us to assess CZP effectiveness in this patient. The grade 3+ anterior chamber inflammation (for both the cells and flare) observed at baseline improved to grade 0 at 3 months post-treatment. Dermatologically, the psoriasis area severity index (PASI) score was 25.4, while the body surface area (BSA) was 88% at baseline. At 3 months after treatment, the scores improved to 2.8 for PASI and less than 1% for BSA. After the treatment, remission has lasted for at least 9 months. No adverse events were seen during the CZP treatment. These findings suggest that CZP could be an effective therapeutic alternative in some refractory anterior uveitis patients with psoriasis vulgaris.<\/jats:p>","DOI":"10.1159\/000495655","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T22:03:06Z","timestamp":1544738586000},"page":"499-503","source":"Crossref","is-referenced-by-count":8,"title":["Successful Certolizumab Pegol Treatment of Chronic Anterior Uveitis Associated with Psoriasis Vulgaris"],"prefix":"10.1159","volume":"9","author":[{"given":"Keiko","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genichiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Momose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-3182","authenticated-orcid":false,"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.0569"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.1.67"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.08.053"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000445285"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-015-2968-4"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nm0307-242"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/09273940802023786"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S31658"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0208-z"}],"container-title":["Case Reports in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/495655","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/495655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:16:31Z","timestamp":1745428591000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000495655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,1,7]]}},"URL":"https:\/\/doi.org\/10.1159\/000495655","archive":["Portico"],"relation":{},"ISSN":["1663-2699"],"issn-type":[{"value":"1663-2699","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]}}}